Kodiak Sciences Net Income Over Time
| KOD Stock | USD 22.07 0.07 0.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kodiak Sciences Performance and Kodiak Sciences Correlation. Will Biotechnology sector continue expanding? Could Kodiak diversify its offerings? Factors like these will boost the valuation of Kodiak Sciences. Expected growth trajectory for Kodiak significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Kodiak Sciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Kodiak Sciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Kodiak Sciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Kodiak Sciences' market price to deviate significantly from intrinsic value.
Understanding that Kodiak Sciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kodiak Sciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Kodiak Sciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Kodiak Sciences and related stocks such as Nurix Therapeutics, Xencor Inc, and Phathom Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRIX | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (21.7 M) | (43.2 M) | (117.2 M) | (166 M) | (143.9 M) | (193.6 M) | (264.5 M) | (238 M) | (226.1 M) |
| XNCR | (11.2 M) | (11.2 M) | (8.6 M) | (60.3 M) | (16.4 M) | (17.6 M) | 23.6 M | (48.9 M) | (70.4 M) | 26.9 M | (63.5 M) | 82.6 M | (55.2 M) | (126.1 M) | (232.6 M) | (209.4 M) | (198.9 M) |
| PHAT | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (209.7 M) | (129.1 M) | (143.9 M) | (197.7 M) | (201.6 M) | (334.3 M) | (300.9 M) | (285.8 M) |
| OCS | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (18.6 M) | (38.7 M) | (88.8 M) | (85.8 M) | (77.2 M) | (81.1 M) |
| EYPT | (2.3 M) | (8.6 M) | (24.8 M) | (11.9 M) | (13.4 M) | 6.3 M | (21.5 M) | (18.5 M) | (53.2 M) | (56.8 M) | (45.4 M) | (58.4 M) | (102.3 M) | (70.8 M) | (130.9 M) | (117.8 M) | (111.9 M) |
| URGN | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (12.7 M) | (1.9 M) | (20 M) | (75.7 M) | (105.1 M) | (128.5 M) | (110.8 M) | (109.8 M) | (102.2 M) | (126.9 M) | (114.2 M) | (108.5 M) |
| ANAB | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | 232 K | (5.4 M) | (4.3 M) | (30.1 M) | (61.7 M) | (97.3 M) | (19.9 M) | (57.8 M) | (128.7 M) | (163.6 M) | (145.2 M) | (130.7 M) | (124.2 M) |
| BBOT | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (3.5 K) | (64.7 M) | (74.3 M) | (66.8 M) | (63.5 M) |
| TNGX | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (52 M) | (58.2 M) | (108.2 M) | (101.7 M) | (130.3 M) | (117.3 M) | (123.1 M) |
| PROK | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (26.7 M) | (55.1 M) | (108 M) | (35.5 M) | (61.2 M) | (70.4 M) | (73.9 M) |
Kodiak Sciences and related stocks such as Nurix Therapeutics, Xencor Inc, and Phathom Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Kodiak Sciences financial statement analysis. It represents the amount of money remaining after all of Kodiak Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Kodiak Sciences | KOD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1200 Page Mill |
| Exchange | NASDAQ Exchange |
USD 22.07
Check out Kodiak Sciences Performance and Kodiak Sciences Correlation. For information on how to trade Kodiak Stock refer to our How to Trade Kodiak Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Kodiak Sciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.